☰

Skip to content

Home
Studies
Study Group
Publications
News
Deltagare / Participants

Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial

2025

JAMA Neurol. 2025 Dec 1;82(12):1251-1256. doi: 10.1001/jamaneurol.2025.3869. PMID: 41082199

Lu M, Kim MJ, Collins EC, Shcherbinin S, Ellinwood AK, Yokoi Y, Brooks DA, Hansson O, Knopman DS, Sims JR, Mintun MA.

JAMA Neurol. 2025 Dec 1;82(12):1251-1256. doi: 10.1001/jamaneurol.2025.3869. PMID: 41082199

2026 A minimally invasive dried blood spot biomarker test for the detection of Alzheimer’s disease pathology
2026 Associations of modifiable and non-modifiable risk factors with longitudinal white matter hyperintensities, amyloid-β and tau – a prospective cohort study
2026 A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease
2025 STEM-PD trial protocol: a multi-centre, single-arm, first-in-human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease
2025 Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group
2025 Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies
2025 Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid
2025 Locus coeruleus-entorhinal cortex tract integrity is linked to plasma tau and glial fibrillary acidic protein
2025 Assessment of myocardial sympathetic innervation with [123I]mIBG myocardial scintigraphy: A comparative study between an Anger and a ring-configured cadmium-zinc-telluride gamma camera.
2025 Characterizing the onset and progression of Alzheimer’s pathologies using amyloid and tau PET imaging and plasma p-tau217
2025 Taurine Intake, Plasma Taurine Concentration, and Dementia Risk: Findings From the Malmö Diet and Cancer Study
2025 CSF pTDP-43 across the Alzheimer’s spectrum: Links to amyloid, APOE and vasculopathy
2025 The tau biomarker cascade is condensed in Down syndrome compared to sporadic Alzheimer’s disease
2025 Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?
2025 Estimating the time course of biomarker changes in Alzheimer’s disease

Follow us

Search for: